Varicella (Chickenpox)

Varicella is a highly contagious infection disease caused by the Varicella zoster virus (VZV). Also known as chickenpox, this disease primarily affects children and presents with characteristic skin rashes, fever and fatigue. Although varicella typically follows a mild course, it can lead to serious complications in individuals with weakened immune systems and adults. It is a preventable disease through vaccination.

Etiology and Epidemiology of Varicella

Varicella is caused by the Varicella zoster virus (VZV), a member of the Herpesviridae family. The virus spreads through respiratory secretions and direct contact with skin lesions. The disease occurs more frequently during late winter and spring months. While varicella is common in childhood, it can also occur in unvaccinated adults.

Varicella is a widespread disease globally. In regions where vaccination is not widespread, the majority of children contract the disease before adolescence. With increased vaccination coverage, there has been a significant decline in varicella cases. However, the risk persists for individuals with compromised immune systems and unvaccinated adults.

Clinical Features and Symptoms

Varicella typically manifests after an incubation period of 10 to 21 days. The disease is evaluated in two distinct stages: the prodromal stage and the rash stage.

1. Prodromal Stage

This stage begins 1 to 2 day before the appearance of the rash and is characterized by mild symptoms:

• Fever
• Fatigue
• Headache
• Loss of appetite

2. Rash Stage

The most distinctive feature of varicella is its characteristic skin rash. The rash usually starts on the trunk and spreads to the face, scalp and extremities. The lesions have the following characteristics:

• Maculopapular lesions: Red, raised spots.
• Vesicles: Fluid-filled blisters.
• Crusts: Formation of scabs after vesicle rupture.

The rash is itchy and lesions in different stages (macule, papule, vesicle, crust) may appear simultaneously. This feature is a key diagnostic feature distinguishing varicella from other rash-causing illnesses.

Complications

Although varicella usually follows a mild course, it can lead to serious complications in some cases:

• Bacterial superinfections: Skin infections such as cellulitis and impetigo may develop due to scratching of lesions.
• Pneumonia: Particularly observed in adults and immunocompromised individuals.
• Neurological complications: Rare but severe complications such as encephalitis, cerebellitis and meningitis may occur.
• Reye syndrome: Liver and brain involvement associated with aspirin use.

Diagnostic Methods

The diagnosis of varicella is usually based on clinical findings. However, laboratory tests may be used in atypical cases or when complications are suspected:

• Direct fluorescent antibody test (DFA): Detection of VZV antigens in vesicular fluid.
• Polymerase chain reaction (PCR): Provides high sensitivity and specificity for detecting VZV DNA.
• Serological tests: Detection of antibodies against VZV in the blood.

Treatment Approaches

The treatment of varicella includes symptomatic and antiviral therapy. Treatment is tailored according to the patient’s age, clinical condition and risk of complications.

Symptomatic Treatment

• Fever control: Paracetamol is used. Aspirin must be strictly avoided due to the risk of Reye syndrome.
• Itch control: Antihistamines and topical calamine lotion are used.
• Fluid intake: Adequate hydration is ensured to prevent dehydration.

Antiviral Treatment

• Acyclovir: Antiviral therapy is recommended for high-risk patients (adults, immunocompromised individuals). Treatment is most effective when initiated within the first 24 hours after rash onset.
• Valacyclovir and famciclovir: Alternative antiviral agents that may be used.

Prevention and Vaccination

The most effective way to prevent varicella is through vaccination. The live attenuated varicella vaccine is included in childhood immunization programs place.

Vaccination Schedule

• First dose: Administered at 12 to 15 months of age.
• Second dose: Administered between 4 and 6 years of age.

The vaccine is also recommended for unvaccinated adults and individuals in high-risk groups.